Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse large B-cell lymphoma.

Andrea K Ng1

  • 1Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115. ang@lroc.harvard.edu

Seminars in Radiation Oncology
|June 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Occult obstructive sleep apnea in survivors of Hodgkin lymphoma following radiation therapy: an atypical and under-recognized phenotype.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.

Blood·2026
Same author

International Guideline Harmonization Group Recommendations for Breast Cancer Surveillance in Childhood, Adolescent, and Young Adult Cancer Survivors After Anthracyclines.

JCO oncology practice·2026
Same author

Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Isolated Nonischemic Left Bundle Branch Block Resulting in Heart Failure in Hodgkin Lymphoma Survivors Post-Radiation.

JACC. Case reports·2025
Same journal

Integrative Medicine for Breast Cancer Survivors.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology and Radiation Therapy: An Essential Evolution.

Seminars in radiation oncology·2026
Same journal

Clinical Trials of Integrative Oncology Interventions for Radiation Therapy: Emerging Evidence and Opportunities.

Seminars in radiation oncology·2026
Same journal

Nonpharmacologic Approaches for Pain Management in Patients With Cancer Treated With Radiation Therapy.

Seminars in radiation oncology·2026
Same journal

Integrative Therapies for Radiation-Related Toxicities in Hematological Malignancies.

Seminars in radiation oncology·2026
See all related articles

Diffuse large B-cell lymphoma (DLBCL) treatment is evolving beyond standard chemotherapy. While rituximab improves outcomes, newer intensive regimens show uncertain benefits and increased toxicity compared to CHOP plus rituximab.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Trials

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
  • Prognostic factors identify patient subgroups with varying treatment outcomes.
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is the standard, with a 40-50% cure rate.

Purpose of the Study:

  • To evaluate the efficacy of novel dose-dense and dose-intense chemotherapy regimens for DLBCL.
  • To compare these regimens against the standard CHOP chemotherapy, with or without rituximab.
  • To assess the role of radiation therapy in localized DLBCL.

Main Methods:

  • Review of phase III trials comparing different chemotherapy regimens for DLBCL.
  • Analysis of studies investigating the addition of rituximab to CHOP chemotherapy.

Related Experiment Videos

  • Evaluation of randomized trials on radiation therapy for localized DLBCL.

    • Main Results:

    • Rituximab significantly improves survival in DLBCL patients when added to CHOP chemotherapy.
    • Dose-dense/intense regimens show uncertain benefits over CHOP plus rituximab and increased toxicity.
    • Radiation therapy improves local control and disease-free survival in localized DLBCL, but does not replace chemotherapy.

    Conclusions:

    • Rituximab-containing CHOP chemotherapy remains a cornerstone for DLBCL treatment.
    • Novel intensive regimens require further validation due to toxicity and unclear advantages.
    • Radiation therapy is a valuable adjunct for localized DLBCL, complementing chemotherapy.